TESTING OF EXPERIMENTAL COMPOUNDS AGAINST AMERICAN MUCOCUTANEOUS AND CUTANEOUS LEISHMANIASIS

CORNELL UNIV MEDICAL COLL NEW YORK J S KEITHLY FEB 81

UNCLASSIFIED DAMD17-80-C-0061 F/G 6/15 NL
TESTING OF EXPERIMENTAL COMPOUNDS AGAINST AMERICAN MUCOCUTANEOUS AND CUTANEOUS LEISHMANIASIS

Annual Progress Report

Dr. Jan S. Keithly

February 1981

Supported by

US Army Medical Research and Development Command
Fort Detrick, Frederick, Maryland 21701

Contract No. DAMD17-80-C-0061

Cornell University Medical College
New York, New York 10021

The findings in this report are not to be construed as an official Department of the Army position unless so designated by other authorized documents.
<table>
<thead>
<tr>
<th>A. Leishmaniasis</th>
<th>Mucocutaneous</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cutaneous</td>
<td></td>
</tr>
<tr>
<td>Leishmania mexicana amazonensis</td>
<td>L. b. braziliensis</td>
</tr>
<tr>
<td>L. m. mexicana</td>
<td>L. b. guyanensis</td>
</tr>
<tr>
<td>Visceral: L. donovani</td>
<td>L. b. panamensis</td>
</tr>
</tbody>
</table>

**Cutaneous and mucocutaneous Secondary Test Systems**

During the first six months of this contract, Leishmania m. mexicana and L. b. panamensis served as standard subspecies for drug screening. Using BALB/c mice, we show that:

1. Both amastigotes and promastigotes yield suitable lesions for drug screening, and that promastigotes grown in insect media are as infective as amastigotes.
19. Key Words (continued)

B. Drugs
- Difluoromethylornithine
- Glucantime
- Pentamidine
- Pentostam
  - SD50, SD90
  - Mode of Action

C. Assays
- Amastigotes
- Promastigotes
- Log
- Stationary
- Infectivity
- SD50
- SD90
- Log
- SD50, SD90
- Mode of Action
- Intracardial
- Intravenous
- Schneider's
- Glycosome
- Growth
- BALB/c mice
- J774 macrophages

20. Abstract (continued)

1. In Schneider's drosophila medium, subcultured promastigotes remain infective. Stationary phase cells are more infective in all media tested.
2. Time to lesion development is stage and dose dependent.

Using Pentostam and Glucantime to treat developed lesions of L. m. mexicana and L. b. panamensis, we show that:

1. Neither drug can cure these infections.
2. Leishmania b. panamensis is more sensitive to Glucantime.
3. The SD50 and 90 for these subspecies is greater than that for visceral L. donovani infections (461 and 800 vs. 15 and 29 or 58, respectively).

Visceral Secondary Test Systems

Using L. donovani in BALB/c mice, we show that:

1. Fourteen day assays are highly reliable whether mice are inoculated IC or IV with 10 million splenic amastigotes or promastigotes.
2. Intracardial inoculations will be employed as they allow direct comparison with hamster primary screening test systems.
3. Unlike its effect against bloodstream trypanosomes, the polyamine inhibitor difluoromethylornithine alone given before, at time of, or after infection does not suppress L. donovani infections in BALB/c mice.

Preliminary ultrastructural evidence (Keithly and Langreth, 1983) indicates that the mode of action of Pentostam may be upon glycolytic enzymes sequ estered within a highly specialized organelle, the glycosome, in leishmania.

A BALB/c macrophage cell line, J774.G.8, supports continuous growth of L. donovani amastigotes in vitro.
FOREWARD

Citations of commercial organizations and trade names in this report do not constitute an official Department of the Army endorsement or approval of the products or services of these organizations.

In conducting the research described in this report, the investigators adhered to the "Guide for Care and Use of Laboratory Animals," prepared by the Committees on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, National Research Council (DHEW Publication No. (NIH) 78-23, Revised 1978).
## TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Documentation Form 1473</td>
<td>1</td>
</tr>
<tr>
<td>Abstract</td>
<td>2</td>
</tr>
<tr>
<td>Foreward</td>
<td>3</td>
</tr>
<tr>
<td>Table of Contents</td>
<td>4</td>
</tr>
<tr>
<td>Index of Figures and Tables</td>
<td>5</td>
</tr>
<tr>
<td>Results</td>
<td>6</td>
</tr>
<tr>
<td>Literature Cited</td>
<td>7</td>
</tr>
<tr>
<td>Figures and Tables</td>
<td>8</td>
</tr>
<tr>
<td>Distribution List</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>11-17</td>
</tr>
<tr>
<td></td>
<td>18</td>
</tr>
</tbody>
</table>
INDEX OF FIGURES

1. Growth of *Leishmania mexicana* in each of 6 media is compared. Blood agar (▲), Schneider's drosophila (■), Medium 199 (○), Mitsuhashi & Maramorosch (□), RE III with (●) and without (○) glucose. Mean of 3 experiments.

2. Growth of *L. m. amazonensis* in each of 6 media. Symbols as in Fig. 1. Mean of 3 experiments.

3. Growth of *L. donovani Sudan* (IS) in each of 5 media. Mean ± SD of three experiments.

4. Infectivity of *Leishmania donovani* primary culture promastigotes harvested from various media is compared with that of amastigotes. Expressed as total LDUs = amastigotes/liver nucleus/mg weight of liver. Mean 3-5 mice from two experiments. Symbols as before except RE III with (▼) and without (●) glucose, respectively.

5. Infectivity of log (4 d) and stationary (7 d) phase primary and subcultured promastigotes of *L. donovani* harvested from blood agar (▲), Schneider's (■), and RE II with glucose (●). Mean 3-5 experiments. Only RE III shows effect upon subculturing.

6. Effect of Pentostam on *L. m. mexicana* (WR 183). Amastigotes from mouse were inoculated ID into tail base on Day 0. Pentostam given in 4-fold dilutions: 58 (■), 116 (▲), and 233 (□) Sbv mkd x 5. Saline (●). No effect in groups showing normal lesion development.

7. Effect of single and double regimes of Pentostam or Glucantime on *L. m. mexicana*. Amastigotes (▲) or subcultured promastigotes from Schneider's medium (■■■) were inoculated with 10⁷ cells. Amastigote-initiated lesions were treated twice: initially at 5 weeks with 15 (*), 29 (▲), or 58 (■) Sbv mkd; and again at 7 weeks at 58, 116 (▼), and 233 (□□□) Sbv mkd, respectively. Pentostam = closed, glucantime = open symbols. No effect was observed.

8. Effect of single dose of either Pentostam or Glucantime upon *L. brasiliensis panamensis* (WR 120). Amastigote from BALB/c donors were injected and treated during early course of infection with: 15 (*), 29 (▲), or 58 (■) Sbv mkd Pentostam (▲) or Glucantime (■■■). No effect was observed.
9. Development of L. b. panamensis and L. m. mexicana from hamster-initiated Infections. Normal course of Infection for WR 120 (●) and WR 183 (○) is compared with that of lesions treated with Glucantime (open) or Pentostam (cls) at 29 (▲ △), 58 (■ □), or 29 and 116 (▼, WR 183) and 29 alone (▼, WR 120).

10. Infectivity for susceptible BALB/c (circles) and resistant DBA/2J (triangles) mice of L. donovani amastigotes after IC (●, ▲) or tail vein (○, △) injection of 10 million cells. Mean ± SD total LDUs from 3-5 animals at 2, 4, 8, 16, & 24 weeks.

INDEX OF TABLES

1. Effect of Pentostam on Leishmania donovani in BALB/c Mice.

2. Effect of RMI 71-782, an Inhibitor of Polyamine Biosynthesis on Leishmania donovani in BALB/c Mice.
RESULTS

During the first six months of this contract, Leishmania mexicana mexicana and L. brasiliensis panamensis served as standard, biochemically characterized cutaneous and mucocutaneous subspecies for drug screening. In general, observations in vivo on these two models for screening may briefly summarized as follows:

1. Both amastigotes and promastigotes (primary or subcultured) may be used to yield palpable lesions for screening.
   a. Promastigotes grown in several insect media (Figs. 1-3) are as infective as amastigotes for mice (Figs. 4).
   b. In one of these media, Schneider's + 20% HIFCS, there is no loss in infectivity through several subcultures (Fig. 5). Stationary phase cells are more infective in all media tested.

2. Rapid and reliable development of lesions for screening occurs when 0.1 ml is inoculated intradermally (ID) or subcutaneously (SC) at the tail base of mice (Figs. 6-9) as follows:

<table>
<thead>
<tr>
<th>TIME (in weeks)</th>
<th>Leishmania brasiliensis</th>
<th>L. mexicana</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amastigotes</td>
<td>(10^7)</td>
<td>3 - 5</td>
</tr>
<tr>
<td>Promastigotes</td>
<td>(10^8)</td>
<td>2 - 3</td>
</tr>
<tr>
<td></td>
<td>(10^7)</td>
<td>3 - 6</td>
</tr>
<tr>
<td></td>
<td>(10^5)</td>
<td>7 - 10</td>
</tr>
</tbody>
</table>

*Time to lesion formation is slightly longer if hamster to mouse inocula are used (Fig. 9).

Since promastigotes of these subspecies show excellent growth in Schneider's medium, are as infective as amastigotes regardless of age in culture or subculture, are the natural infective agent, and can be counted accurately to produce reliable lesions within a short time, we plan to use them to initiate infections.
Drug screening has chiefly consisted of establishing standard doses of Pentostam and Glucantime. The following is a brief summary of our results for L. m. mexicana and L. b. panamensis:

1. There is no effect of either Pentostam or Glucantime upon early or late amastigote or promastigote-initiated lesions for either subspecies when doses up to 233 mg/kg/day antimony x 5 are used (Figs. 6-9).

2. Both subspecies respond similarly to Pentostam, chronic infections with L. b. panamensis may be more sensitive to Glucantime during treatment (Fig. 9).

3. Although there is a temporary effect upon early amastigote-initiated infections, even after retreatment lesion size increases by week 9 to former levels (Figs. 7-9).

4. The SD50 and SD90 for these subspecies is well above that for visceral leishmaniasis (29 and 58 Sbv mkd) in BALB/c mice (Table I), and appears to be approximately 461 and 800 Sbv mkd, respectively (1-3, 9-10, these data).

In succeeding months, we plan to initiate drug tests using another L. m. mexicana (LTB 0016) and L. b. brasiliensis (M 1128). The decision to substitute these strains for those originally tested is based upon the following data accumulated during the first 6 months of this contract. Although L. m. mexicana WR 183 was initially isolated by P.C.C. Garnham in Panama and is considered a type specimen, this strain routinely visceralized in hamsters (JSK, unpublished observations) and BALB/c mice (these data). Therefore, we have selected another well-characterized strain of this subspecies which does not. Furthermore, although initial experiments using a well-characterized strain of L. b. brasiliensis from Tres Bracos, Brazil (LTB 0018) are still promising, we have yet to establish reliable lesions in large numbers of BALB/c mice. Therefore, we have substituted M 1128, another well-characterized strain from Belem, Brazil which grows well in vivo and in vitro.

In order to complete our roster of the most common South American cutaneous and mucocutaneous subspecies, we have also begun testing L. b. guyanensis (M 1142) and L. m. amazonensis (LV72 & 78; LTB 150492). Both of these subspecies are clinically and biochemically unique from their cohorts, and the latter has been extensively used in vitro for drug-screening. Apparently, L. b. guyanensis contains the highest amount of an unusual cyclopropane fatty acid (G.G. Holz, pers. comm.). This lipid relic from a predominantly prokaryotic and/or plant ancestry seems to be utilized efficiently (5) and may be an ideal target for chemotherapy in mucocutaneous species. Therefore, this subspecies merits special consideration. In summary, these mucocutaneous and cutaneous subspecies are currently being screened:
L. brasiliensis complex

L. b. brasiliensis (M 1128, LTB 0018)
L. b. guyanensis (M 1142)
L. b. panamensis (WR 120)

L. mexicana complex

L. m. amazonensis (LV 72 & 78, LTB 150492)
L. m. mexicana (LTB 0016)

LTB = Tres Bracos, Brazil
LV = Liverpool, England
M = Belem, Brazil

To augment ongoing studies by W.L. Hanson, we have initiated drug screening against L. donovani 1S (Sudan) in our mouse model. Results over the first six months may be summarized as follows:

1. Mice inoculated IC or IV with $10^7$ splenic amastigotes or promastigotes yield highly reproducible results if amastigotes in liver impressions are enumerated two weeks after infection (Fig. 10). Seven day assays are not reliable for mice, although they are highly reliable for hamsters.

2. Peak numbers of parasites occur in livers of BALB/c mice 4 weeks after infection (Fig. 10). Since IC inoculation is faster, and just as reliable as IV injection, we prefer to use it. It also allows direct comparison with Hanson's hamster data.

3. In addition, to determining the SD90 for Pentostam in mice (Table 1), we have tested the polyamine inhibitor D-difluoromethylornithine (DFMO) against L. donovani (Table 2). Although DFMO is active against African trypanosomes, when given alone in a similar regime (1%) in drinking water, it was ineffective against leishmaniasis.

4. Currently, we are testing two WRAIR compounds (BJ 84232 and BJ 58410) against visceral leishmaniasis in BALB/c mice.

In addition to these screening data, we have some observations on the possible mode of action of Pentostam in vivo, which may help explain the regular recurrence of mucocutaneous and cutaneous lesions after treatment. Ultrastructural evidence obtained from L. mexicana 1156 infected hamsters (#) and recent
subcellular and biochemical data on *L. m. mexicana* amastigotes in vitro (D. Hart, pers. comm.), indicate that these subspecies may have unusual pathways in organelles sensitive to the drug. Unlike pentamidine-treated *L. tropica* (4), the ultrastructure of *L. mexicana* amastigotes in hamster nose dermis still showed intact nuclei and kinetoplasts 8 weeks after infection and treatment with Pentostam (6). However, a large population of microbodies normally seen within the cytoplasm of amastigotes from placebo-treated animals was completely absent. These data, together with those of Hart, who showed that:

1. Pentostam inhibits amastigote to promastigote transformation prior to cell division and during peak metabolism,
2. β-oxidation of fatty acids is an important energy-generating pathway for *L. mexicana* amastigotes,
3. The enzymes associated with this pathway are located in a P2 small microsomal fraction (=glycosomal) of these cells,

suggest that although Pentostam disrupts one amastigote pathway, the nucleus and kinetoplast are still intact. Therefore, parasites which temporarily switch to a less efficient pathway can resume proliferation and can cause lesion regrowth once drug pressure is removed. That cutaneous and mucocutaneous species might be more resistant to this drug than *L. donovani* is not surprising, since there are remarkable metabolic differences and compartmentation of enzymes in various species of *Leishmania* (7, J. Decker-Jackson and D. Hart, pers. comm.).

**In vitro models.**

In addition to these data, we have recently initiated an in vitro system for continuously culturing *L. donovani* in a macrophage cell line (J774), initially obtained from a BALB/c reticulosarcoma (8), by weekly passing 3 ml containing ~15 x 10⁶ cells into 30 ml fresh medium and incubating in 5% CO₂ at 35⁰ C. Currently, *L. donovani* has been maintained in continuous culture for two months, and we are now defining the conditions necessary for maintaining *L. b. panamensis* and *L. m. mexicana* in this same system. We think this cell line will be a valuable correlate of our in vivo screening once active drugs have been identified. In this system, within one week, a newly seeded culture becomes 100% infected and cells are extremely easy to handle.
LITERATURE CITED


Figure 1

GROWTH OF Leishmania mexicana mexicana PROMASTIGOTES IN VARIOUS MEDIA

Figure 2

GROWTH OF Leishmania mexicana amazonensis PROMASTIGOTES IN VARIOUS MEDIA
Figure 3

GROWTH OF *Leishmania donovani* PROMASTIGOTES IN VARIOUS MEDIA

CELLS/mL MEDIUM

DAYS
Figure 4

INFECTIVITY OF PROMASTIGOTES FROM VARIOUS MEDIA FOR BALB/c MICE

Figure 5

LDUs in liver at 16 days

Type of cultured promastigotes
Figure 6
EFFECT OF PENTOSTAM ON *L. mexicana mexicana* LESIONS IN BALB/c MICE

Mean lesion size ± SD (area)

Weeks

Placebo ○
500 µg/d x 5 ●
116 ▲
232 ○

Drug treatment

Figure 7
DEVELOPMENT OF *Leishmania mexicana mexicana* LESIONS IN BALB/c MICE
Single and Double Regimes of SbIII

Average lesion size (area)

Weeks

Amastigote - Solid line
Promastigote - Dashed line
Pentostam - Closed symbols
Gloxintime - Open symbols
15 µg/d x 5 ○
28 ○
58 ▲
116 ●
232 ○
Placebo ○

Drug treatment
Figure 8
DEVELOPMENT OF *Leishmania brasilienensis panamensis* LESIONS IN BALB/c MICE
Single Regime with Sb

![Graph showing the development of lesions in BALB/c mice with Sb treatment.](image)

Figure 9
EFFECT OF Sb ON *Leishmania brasilienensis panamensis* AND *L mexicana mexicana* LESIONS IN BALB/c MICE

![Graph showing the effect of Sb on lesions in BALB/c mice.](image)
Figure 10

INFECTIVITY OF Leishmania donovani AMASTIGOTES FOR MICE

LDUs/liver

Weeks

10^2 10^3

BALB/C DBA/2J

IC IC

IV IV
TABLE 1
Effect of Pentostam on *Leishmania donovani* in BALB/c Mice

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Amastigotes in Liver at 16 Days*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo</td>
<td>2213 ± 424 (10)</td>
</tr>
<tr>
<td>Pentostam</td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>116 ± 115 (10)</td>
</tr>
<tr>
<td>104</td>
<td>3 ± 2 (10)</td>
</tr>
<tr>
<td>233</td>
<td>0 (10)</td>
</tr>
</tbody>
</table>

*Expressed as LDUs = amastigotes/liver cell nuclei/mg/liver

TABLE 2
Effect of RMI 71,782, an Inhibitor of Polyamine Biosynthesis on *Leishmania donovani* in BALB/c

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Number of Amastigotes in Liver at 16 Days</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo</td>
<td>7 ±2 x 10⁷ (5)</td>
</tr>
<tr>
<td><em>RMI 71,782</em></td>
<td></td>
</tr>
<tr>
<td>3 days pre-</td>
<td>9 ±1 x 10⁷ (5)</td>
</tr>
<tr>
<td>Time of infection</td>
<td>7 ±6 x 10⁷ (5)</td>
</tr>
<tr>
<td>3 days post-</td>
<td>8 ±5 x 10⁷ (5)</td>
</tr>
<tr>
<td>†Pentostam</td>
<td>5 ±4 x 10⁶ (5)</td>
</tr>
</tbody>
</table>

*200 mg/kg/day in drinking water for total of 10 days.
†13 mg/kg/day Sbv IP x 5 days
### DISTRIBUTION LIST

<table>
<thead>
<tr>
<th>Copies</th>
<th>Address</th>
</tr>
</thead>
</table>
| 12     | Director  
Walter Reed Army Institute of Research  
Walter Reed Army Medical Center  
ATTN: SGRD-UWZ-C  
Washington, D.C. 20012 |
| 4      | Commander  
U.S. Army Medical Research and Development Command  
ATTN: SGRD-RMS  
Fort Detrick  
Frederick, MD 21701 |
| 12     | Defense Technical Information Center (DTIC)  
ATTN: DTIC-DDA  
Cameron Station  
Alexandria, VA 22314 |
| 1      | Dean  
School of Medicine  
Uniformed Services University of the Health Sciences  
4301 Jones Bridge Road  
Bethesda, MD 20014 |
| 1      | Commandant  
Academy of Health Sciences, U.S. Army  
ATTN: AHS-CDM  
Fort Sam Houston, TX 7834 |
| 1      | Ann Stanford  
Research Administrator  
Office of Research and Sponsored Programs  
Cornell University Medical College  
1300 York Avenue  
New York, NY 10021 |